Whitaker Platform Presentations

• Welcome and Introduction ¦ Michael Racke, MD
• A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
• Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
• Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
• Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
• Q&A, Closing ¦ Michael Racke, MD

Access to Care

• Practice Management ¦ Edward J. Fox, MD, PhD
• Quality Measures and Outcomes ¦ Sarah Benish, MD
• Debate: Community-based Centers vs. Hospital-based Centers ¦ Edward J. Fox, MD, PhD; John Corboy, MD
• Q&A ¦ Panel

Essential Topics in Caring for Persons with Progressive MS 

• Managing Difficult Conversations ¦ Marijean Buhse, PhD, MP-C, MSCN
• Applying Primary Palliative Care to Those with Advanced MS ¦ Rachael Stacom, MS, ANP-BC, MSCN
• Empowering Persons with MS: Planning for Future Needs ¦ Patti Nelson Reade, RN, Esq. CELA
• Panel Discussion 

Caring for Women Across the Reproductive Lifespan

• Welcome and Overview ¦ Riley Bove, MD
• Counseling Women about Contraception and the Menstrual Cycle ¦  Riley Bove, MD
• Pregnancy and MS: Safely Navigating Childbearing, from Pre-pregnancy Planning to the Post-partum Period ¦  Maria Houtchens, MD, MMsci
• Menopause: A Time of Changes and an Opportunity to Re-evaluate Comprehensive Wellness and Care ¦ Riley Bove, MD
• Healthy Aging Beyond the Menopause: Tackling “Below the Belt” Function and Other Aspects of Wellness ¦ Tamara Kaplan, MD

An MS Health Professional’s Guide to Cannabis 

Allen C. Bowling, MD, PhD

• History, Botany, Pharmacology
• Efficacy and Safety
• Drug Interactions and Special Considerations
• The Critical Role of MS Health Professionals

Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 1)

• History of Multiple Sclerosis ¦ Randall T. Schapiro, MD, FAAN
• The Natural History of MS (Epidemiology, Immunology, Pathophysiology, Phenotypes) ¦ Bruce Cohen, MD
• Making the Diagnosis: Disease Mimics, Use of Paraclinical Tools ¦ Derrick Robertson, MD
• Primary Progressive MS: Diagnosis, Clinical Course, and Long-term Management ¦ Patricia K. Coyle, MD

Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)

• RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
• Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
• Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
• Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN

Multidisciplinary Management of Chronic Pain in MS

• Introduction to Multidisciplinary Management of Chronic Pain in MS ¦ Kevin Alschuler, PhD
• Management of the MS Patient with Chronic Pain ¦ Brett R. Stacey, MD
• Is There a Role for Opioids in MS Pain Management? A Case-Based Discussion ¦ Pamela Stitzlein Davies, MS, ARNP, FAANP
• Physical Activity and Chronic Pain in MS ¦ Robert W. Motl, PhD
• Cognitive Behavioral Interventions for Chronic Pain ¦ Dawn M. Ehde, PhD
• Q&A ¦ Panel

The Importance of Community Based Programs to Enhance Comprehensive MS Care

• Welcome and Introduction of Speakers ¦ Brian Hutchinson, PT, MSCS
• Community-Based Wellness Models for Chronic Disease ¦ Brian Hutchinson, PT, MSCS
• Building MS Communities, Expanding the Continuum of Care ¦ James Bowen, MD
• A Community Based Yoga Program for People with MS: The Power of Connection ¦ Megan Weigel, DNP, ARNP-c, MSCN
• The Multiple Sclerosis Achievement Center: A Day Program Model for People with MS ¦ Brian Hutchinson, PT, MSCS

Palliative Care in MS

• Introduction ¦ Sarah Morrow, MD, MS, FRCPC
• Description of the Consensus Conference-November 2018 ¦ Lori Mayer, DNP, MSN, RN, MSCN
• Models of Palliative Care ¦ Rachel Stacom, MS, ANP-BC, MSCN
• Clinical Experience Using the Palliative Care Model ¦ Benzi Kluger, MD, MS, FAAN
• Case Studies with Learner Participation ¦ Panel

Update on Pediatric MS and Related Disorders

• Overview: Changing Landscape in MS and Neuroinflammatory Disorders in Youth ¦ Giulia Longoni, MD
• Do Lifestyle and Environment Make a Difference in Pediatric MS? ¦ Ann Yeh, MD
• Therapies for Pediatric MS ¦ Jennifer Graves, MD, PhD, MAS
• Transitional Issues in Youth with MS ¦ Jennifer Boyd, RN, MHSc, MSCN

Integrative Medicine: An Essential But Neglected Component of Comprehensive MS Care

• Introduction, Relevance to Comprehensive Care, Science and Clinical Application, Research Update ¦ Allen C. Bowling, MD, PhD
• Calorie-Restriction and Other Dietary Modification Strategies for MS Course ¦ Kathryn Fitzgerald, ScD, ScM
• Constraint-Induced Movement Therapy ¦ Victor Mark, MD
• Can High Intensity Training in MS Further Optimize Exercise Therapy Outcome? ¦ Charly Keytsman, PhD

Fundamentals of Multiple Sclerosis Care 2019 (Part 3)

• Multidisciplinary Approach to Symptom Management ¦ Beverly Layton, RN, BSN, CCRC, MSCN
• Pearls from Advanced Practice: Disease Modifying Therapies ¦ Marie Moore, MSN, FNP, MSCN
• Emerging Role of Pharmacists in MS Centers ¦ Brittany Denson, PharmD
• Current Options in Comprehensive Fatigue Management ¦ Patricia Pagnotta, ANP-C, MSCN
• Symptoms Below the Belt: Strategies in the Management of Elimination and Sexual Dysfunction ¦ Marie Namey, APRN, MSN, MSCN

Mental Health Care Delivery Models for Patients with MS

• The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
• Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
• The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
• Q&A
• Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
• The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
• Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
• Q&A ¦ Panel

Platform Presentations: Disease Assessment and Management

• DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
• DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
• DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
• DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
• DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
• DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD

Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS

• Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS ¦ Gloria von Geldern, MD
• Encouraging Wellness Behaviors and Integrating Wellness into Neurologic Care ¦ Annette Wundes, MD
• Guiding Patients through the Complex World of MS Care ¦ Debra Cramer, RN
• Physiatry and Rehabilitation Therapy Interventions to Promote Wellness ¦ Gloria Hou, MD
• Promoting Wellness through Education, Employment, and Volunteering ¦ Joe Stuckey, MS, CRC
• Promoting Wellness Behaviors through Health Behavior Change Interventions ¦ Samantha Artherholt, PhD

Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management

• Introduction ¦ Jodie K. Haselkorn, MD, MPH
• Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
• Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
• Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
• Implementing Strategies into a Clinical Setting ¦ Panel

Sex and MS: How to Help Patients with MS Who Experience Sexual Dysfunction

Kimberly Castelo, MS, LMFT, CST

Psychopharmacology and MS: Review and Update for Clinicians

• Psychopharmacology Overview: Classification, Indications, Mechanism of Action, and Common Adverse Effects of Psychopharmacological Agents ¦ Jane Erb, MD
• Use of Psychotropics in MS: Antidepressants, Antianxiety Agents, Mood Stabilizers, Antipsychotics, Cognitive Enhancers, and Cannabis  ¦ Laura Safar, MD
• Psychotropics Algorithm Selection Based on Clinical Scenario – Clinical Vignettes Discussion with Audience Participation  ¦ Panel

Presidential Lecture: Use and Abuse of the McDonald Criteria in MS Diagnosis

Fred D. Lublin, MD

Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 1)

• History of Multiple Sclerosis ¦ Randall T. Schapiro, MD, FAAN
• The Natural History of MS (Epidemiology, Immunology, Pathophysiology, Phenotypes) ¦ Bruce Cohen, MD
• Making the Diagnosis: Disease Mimics, Use of Paraclinical Tools ¦ Derrick Robertson, MD
• Primary Progressive MS: Diagnosis, Clinical Course, and Long-term Management ¦ Patricia K. Coyle, MD

Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)

• RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
• Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
• Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
• Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN

Update on Pediatric MS and Related Disorders

• Overview: Changing Landscape in MS and Neuroinflammatory Disorders in Youth ¦ Giulia Longoni, MD
• Do Lifestyle and Environment Make a Difference in Pediatric MS? ¦ Ann Yeh, MD
• Therapies for Pediatric MS ¦ Jennifer Graves, MD, PhD, MAS
• Transitional Issues in Youth with MS ¦ Jennifer Boyd, RN, MHSc, MSCN

Practical Considerations in Relapse Management and Disease Modifying Therapy (DMT) Decision Making

Bryan Walker, MHS, PA-C, MSCS; Stephanie Agrella, PhDc, MSN, RN, ANP-BC, MSCN

Basic Immunology for the Non-immunologist

• How Does the Immune System Protect Us? ¦ Lisa Fox, PA
• What Causes CNS Inflammation in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
• How Do the Current DMTs Affect the Altered Immune Response in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN

Advanced Immunology for the Non-immunologist

• The Innate Immune System: An Emerging Target in MS ¦ Michael Kornberg, MD, PhD
• The Innate Immune System: Effect of MS Disease Modifying Therapies ¦ Robert J. Fox, MD
• Q&A

Platform Presentations: Disease Modifying Therapy

• DXM01: Efficacy and Safety of Alemtuzumab in Patients of African Descent in CARE-MS I and II: 8-Year Follow-up (TOPAZ Study) ¦ Annette Okai, MD
• DXM02: Treatment Patterns of Disease-Modifying Therapy Among Pediatric Patients with Multiple Sclerosis in the United States ¦ Chinmay Deshpande, PhD
• DXM03: Changes in the Immune Cell Profile, Clinical and Safety Outcomes in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis: Interim Results of the FLUENT Study ¦ Yang Mao-Draayer, MD, PhD
• DXM04: Real-World Efficacy of Delayed-Release Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 24-Month Interim Results from ESTEEM ¦ Mitzi Joi Williams, MD
• DXM05: The Effects of Cladribine Tablets on Reduction in MRI Lesions Are Consistent across Subgroups in the ORACLE-MS ¦ Study Thomas Leist, MD
• DXM06: Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing MS over 48 Weeks: A Phase II Study ¦ Jerry Wolinsky, MD (This speaker has opted not to publish this presentation.)

Platform Presentations: Disease Assessment and Management

• DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
• DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
• DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
• DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
• DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
• DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD

Beyond the PI: Drug-Drug Interactions (DDIs), Monitoring and Management

• Precision Medicine and Applied Pharmacology for Anti-Depressants, Anti-Psychotics to Assist in Drug Selection and Monitoring to Avert Comorbidities in Patients with MS ¦ Rebecca Barnhart, PharmD, BCPP
• Anatomy of Pharmacokinetic/ Pharmacodynamic Drug Interaction Implications ¦ Felecia Hart, PharmD, MSCS

John F. Kurtzke Memorial Lecture: A Novel Subtype of Multiple Sclerosis

Bruce D. Trapp, PhD

Whitaker Platform Presentations

• Welcome and Introduction ¦ Michael Racke, MD
• A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
• Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
• Dysfunctional RNA Binding Protein Biology ss Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
• Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
• Q&A, Closing ¦ Michael Racke, MD

Mechanisms of Disease Pathogenesis in MS

• Control of Immunopathology in CNS Autoimmunity ¦ Thomas Korn, MD, PhD
• Regulation of Autoimmune CNS Disease by IL-17 ¦ Rachel R. Caspi, PhD
• Environmental Regulation of Astrocyte Pathogenic Activities ¦ Francisco J. Quintana, PhD
• MS: An Immune Miscommunication Disease? ¦ Burkhard Becher, PhD
• Distinct Roles for CD8 T Lymphocytes in Central Nervous System Autoimmunity ¦ Joan Goverman, PhD
• How Do B Cell Directed Therapies Impact MS? ¦ Jennifer Gommerman, PhD
• How IL-1 Regulates CNS Inflammation ¦ Ari Waisman, PhD

Presidential Lecture: Use and Abuse of the McDonald Criteria in MS Diagnosis

Fred D. Lublin, MD

Understanding the Mechanism of Action of B-cell Depleting Drugs: What Does that Reveal about the Role of B-cells in MS?

• Introduction ¦ Gregory Wu, PhD
• The Role of B Cell Antigen Presentation in EAE and MS ¦ Gregory Wu, PhD
• B cell Responses of Adult and Pediatric Transverse Myelitis ¦ Nancy Monson, PhD
• Disease Modifying Therapies Reveal Inflammatory and Anti-inflammatory Functions of B-cells in MS ¦ Robert Axtell, PhD
• Mechanisms of Action of Ocrelizumab in MS ¦ Anne Cross, MD
• Wrap-up ¦ Anne Cross, MD

Neuromyelitis Optica Spectrum Disorders: Current Issues in Diagnosis and Management

• Overview ¦ Brian Weinshenker, MD
• Diagnosis
  • Limited Syndromes: Myelitis, Optic Neuritis, Single and Recurrent ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
  • Brain Syndromes in NMOSD ¦ Marcelo Matiello, MD
  • Overlap of MS and NMO ¦ Anu Jacob, MD
  • NMO “Mimics” ¦ Anu Jacob, MD
  • Comorbidities: Autoimmunity (non-CNS, CNS) ¦ Brian Weinshenker, MD
  • Paraneoplastic NMOSD ¦ Marcelo Matiello, MD
• Serologic Diagnosis
  • False Positive ¦ Marcelo Matiello, MD
  • False Negative (including MOG) ¦ Anu Jacob, MD
• Management
  • Relapse Management: Consensus and Controversies ¦ Marcelo Matiello, MD
  • Indication for and Initial Treatment Choices for Long Term Therapy: Consensus and Controversies ¦ Anu Jacob, MD
  • Aggressive Disease/Treatment Failure ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
  • Pregnancy ¦ Brian Weinshenker, MD
  • Onset in Pregnancy/Relapse in Pregnancy
  • Maintenance Treatment: Planned and “Unplanned” Pregnancy
  • Stopping Therapy ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
• Conclusion Brian Weinshenker, MD

The Future of MS Imaging

• Welcome and Goals: Presenting the NAIMS Cooperative ¦ Daniel S. Reich, MD, PhD
• Role of Advancing Imaging in Diagnosing (and Not Misdiagnosing) MS ¦ Andrew Solomon, MD
• Stretch ¦ Daniel Reich, MD, PhD
• Role of Advanced Imaging in Predicting and Tracking MS Course ¦ Jiwon Oh, MD, PhD, FRCPC
• Role of Advanced Imaging in Unraveling MS Pathophysiology ¦ Pascal Sati, PhD
• Discussion and Wrap-up

John Whitaker Memorial Lecture: Therapeutic Exploitation of Crosstalk Between the Immune and Nervous Systems

Frauke Zipp, MD

Whitaker Track Invited Lectures

• Welcome and Introduction ¦ Michael K. Racke, MD
• The Role of Stress Granules and RNA Binding Protein Dysfunction in the Pathogenesis of Neurodegeneration in MS ¦ Michael Levin, MD, FRCPC, FAAN, FANA
• Serum Neurofilament Light Chain: The Neurologist‘s C-reactive Protein? Can We Rely on Serum NfL in the Future? ¦ Jens Kuhle, MD, PhD
• Disability-specific and Sex-specific Approach to Neuroprotection in MS ¦ Rhonda Voskuhl, MD
• Q&A, Closing ¦ Michael K. Racke, MD

Genetic Risk

• Introduction and Objectives ¦ Sergio E. Baranzini, PhD
• Genetic Susceptibility in MS ¦ Stephen Sawcer, MD, PhD
• From Genes to Pathways: How Common Variants in DNA Can Result in MS Risk ¦ Sergio E. Baranzini, PhD
• The Role of Rare DNA Variants in MS Susceptibility ¦ Chris Cotsapas, PhD
• MS Genetics in Non-Europeans ¦ Jacob McCauley, PhD

Basic Immunology for the Non-immunologist

• How Does the Immune System Protect Us? ¦ Lisa Fox, PA
• What Causes CNS Inflammation in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
• How Do the Current DMTs Affect the Altered Immune Response in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN

Advanced Immunology for the Non-immunologist

• The Innate Immune System: An Emerging Target in MS ¦ Michael Kornberg, MD, PhD
• The Innate Immune System: Effect of MS Disease Modifying Therapies ¦ Robert J. Fox, MD
• Q&A

Challenges and Considerations with Infusible Therapies

All Presentations

• Introduction ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
• Pre-infusion Preparation ¦ Colleen Harris, MN, NP, MSCN, MSCS
• Infusions and Maintenance of Therapies ¦ Denise Bruen, MSN, APRN-BC, MSCN
• Case Studies ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN

• Introduction ¦ Jodie K. Haselkorn, MD, MPH
• Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
• Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
• Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
• Implementing Strategies into a Clinical Setting ¦ Panel

• Course Overview ¦ Marie Namey, APRN, MSCN
• Communication: The CPR of Healthcare ¦ E. Mary Johnson, RN, BSN, NE-BC
• Shared Decision Making: Patient Centered Health Care ¦ Marie Namey, APRN, MSCN; Ellen Reardon, RN, MSN
• Panel Discussion ¦ Panel

Managing Fatigue and Sleep Disorders in People with MS

All Presentations

• Invisible Symptoms: Prevalence Statistics of Fatigue and Sleep Disorders in MS ¦ Amy Sullivan, PsyD, ABPP
• Modifying Empirically Validated Sleep Interventions for the MS Population ¦  Michelle Drerup, PsyD, DBSM
• Research and Outcome Data on Treatment of Insomnia in the MS Population ¦  Catherine Siengsukon, PT, PhD
• Ask the Experts ¦ Panel

Whitaker Platform Presentations

• Welcome and Introduction ¦ Michael Racke, MD
• A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
• Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
• Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
• Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
• Q&A, Closing ¦ Michael Racke, MD

Psychopharmacology and MS: Review and Update for Clinicians

• Psychopharmacology Overview: Classification, Indications, Mechanism of Action, and Common Adverse Effects of Psychopharmacological Agents ¦ Jane Erb, MD
• Use of Psychotropics in MS: Antidepressants, Antianxiety Agents, Mood Stabilizers, Antipsychotics, Cognitive Enhancers, and Cannabis  ¦ Laura Safar, MD
• Psychotropics Algorithm Selection Based on Clinical Scenario – Clinical Vignettes Discussion with Audience Participation  ¦ Panel

Utilizing the Power of the Arts in MS Care: Everyone Benefits

All Presentations

• Introduction ¦ Francois Bethoux, MD
• Medical Humanities through Arts in MS – Reflective Writing and Visual Arts  ¦ Ahmed Obeidat, MD, PhD
• Use of Therapeutic Arts in an MS Clinic  ¦ Lisa Gallagher, MA, MT-BC
• Evidence Supporting the Use of the Arts in the Management of MS  ¦ Francois Bethoux, MD
• Musical Experience  ¦ Lisa Gallagher, MA, MT-BC

Affective Disorders and Personality Changes in MS

• Introduction ¦ Frederick W. Foley, PhD
• Epidemiology of Affective Disorders in MS: What We Know and What Gaps there are in Knowledge ¦ Scott B. Patten, MD
• MRI Correlates and Pharmacological Treatment of Affective Disorders in MS ¦ Anthony Feinstein, MD, PhD
• Personality Traits in Relation to Cognitive Impairment and Brain MRI in MS ¦ Ralph H B Benedict, PhD, ABPP-CN

Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)

• RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
• Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
• Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
• Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN

Supporting and Caring For Each Other While Living with MS: The Support Partners’ Perspective

All Presentations

• Introductions and Orientation to Session ¦ Deborah Miller, PhD, LISW
• Presentation and Discussion of Vignette 1: Teen with MS and Mother ¦ Rosalind Kalb, PhD
• Presentation and Discussion of Vignette 2: Newly Diagnosed Couple ¦ Matthew Sacco, PhD
• Presentation and Discussion of Vignette 3: Older Couple ¦ Lucille Carriere, PhD

Mental Health Care Delivery Models for Patients with MS

• The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
• Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
• The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
• Q&A
• Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
• The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
• Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
• Q&A ¦ Panel

Managing the Suicidal Patient in Your Clinic: Red Flags, Ethical Considerations & Emotional Aftermath

All Presentations

• What We Know about Depression and Suicide in MS and their Impact on Individuals and their Families ¦ Rosalind Kalb, PhD
• Before & After: Recognizing Red Flags, Dealing with the Aftermath ¦ Mary Alissa Willis, MD
• Managing the Suicidal Patient in a Private Practice Setting: Legal and Ethical Considerations ¦ Amanda Rohrig, PT; Lauren R. Sankary, JD, MA
• Interdisciplinary Discussion of Suicide-related Challenges ¦ Panel

Platform Presentations: Psychosocial: Cognition, Depression

• PSY01: Cognition Following Mesenchymal Stem Cell Therapy in Multiple Sclerosis: An Interim Analysis ¦ Lisa Walker, PhD
• PSY02: Contributions of the Rey Auditory Verbal Learning Test to Cognitive Impairment on the Brief International Cognitive Assessment for Multiple Sclerosis ¦ Abbey Hughes, PhD
• PSY03: Neurobehavioral Correlates of Hazardous Cannabis Use in Multiple Sclerosis ¦ Abbey Hughes, PhD
• PSY04: Using Connectome-Based Predictive Modeling to Derive Neuromarkers of Cognition in MS ¦ Ruchika Prakash, PhD
• PSY05: Correlates of Cognitive Performance and Perceived Cognitive Abilities Among Hispanic and Black Individuals with Multiple Sclerosis ¦ Alexa Stuifbergen, RN, PhD, FAAN
• PSY06: How Anxiety and Fatigue Interact to Interfere with Processing Speed in MS ¦ Caroline Altaras, MA

Case Studies in Cognition in MS

Jeffrey Wilken, PhD; Lori Ann Kostich, MS, CCC-SLP

Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management

• Introduction ¦ Jodie K. Haselkorn, MD, MPH
• Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
• Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
• Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
• Implementing Strategies into a Clinical Setting ¦ Panel

Sex and MS: How to Help Patients with MS Who Experience Sexual Dysfunction

Kimberly Castelo, MS, LMFT, CST

Current Topics and Trends in MS Rehabilitation (Part 1)

• Neuromodulation in MS ¦ Hesham Abboud, MD, PhD
• Neuromuscular and Cardiovascular Considerations for Exercise in MS ¦ Alexander Ng, PhD, FACSM

Current Topics and Trends in MS Rehabilitation (Part 2)

• MS Rehab Research: Turning a Burning Clinical Question into a Research Project  ¦ Donna Fry, PT, PhD; Herb Karpatkin, PT, DSc, NCS, MSCS; Lori Ann Kostich, MS, CCC-SLP, MSCS

Current Topics and Trends in MS Rehabilitation (Part 3)

• Occupational Therapy Assessment and Intervention in Multiple Sclerosis: A Behavior-based Approach ¦ Shaina Meyer, OTR/L, MSCS; Rebecca Cunningham, OTD, OTR/L
• Computer Based Rehab Outcome Measures: The Future is Now ¦ Matt Sutliff, PT, DPT, MSC

Platform Presentations: Rehabilitation

• RHI01: Environmental Correlates of Physical Activity in Persons with Multiple Sclerosis ¦ Stephanie Silveira, PhD
• RHI02: Physical Activity and Walking Performance across the Lifespan in Multiple Sclerosis ¦ Jessica Baird, PhD
• RHI03: Physical and Cognitive Fatigue across the Lifespan in Persons with Multiple Sclerosis ¦ Catherine Jones, MSPH
• RHI04: Psychometric Comparisons of Computer-Adaptive Test and Standard Balance and Walking Scales to Assess Functional Mobility in People with MS ¦ Hina Garg, PT, MS, PhD, NCS
• RHI05: Persons with Multiple Sclerosis with Severe Disability Exhibit Muscular Strength Asymmetries in Both Upper and Lower Extremities ¦ John Farrell III, PhD
• RHI06: Manual Dexterity and Computerized Cognitive Testing in People with Multiple Sclerosis: Motor Domain Reflects More Than Just What Is in the Hand ¦ Jared Srinivasan, BA

New Developments in MS Rehabilitation and Telerehabilitation (VA MSCoE)

All Presentations

• Introduction ¦ Jodie Haselkorn, MD, MPH
• Overview of Existing Telerehabilitation in MS in Current Practice ¦ Mitchell T. Wallin, MD, MPH
• Novel Applications of Telerehabilitation Technology ¦ Shane Chanpimol, PT, DPT
• Strategies to Enhance Function in MS through Rehabilitation Intensity, Duration and Timing ¦ Jodie Haselkorn, MD, MPH
• Current Evidence-based Rehabilitation Interventions for Fall Prevention in MS ¦ Michele Cameron, MD, PT, MCR
• Discussion ¦ Panel

Opening Lecture: Mountains to Climb: The Cause, Treatment and Care of MS in the Pacific Northwest

James Bowen, MD

Clinical Trials and Technology: What We Know, What is Coming?

• Responsibilities of the Investigator: Current Use of Electronic Data Capture ¦ Andrew Goodman, MD, FAAN, FANA
• Research Technology in the Clinic: A Learning Health Care System ¦ Kelsey Yoo, PA
• Telemedicine Techniques in Clinical Research: Current and Future Use ¦ Lee Gerwitz, MD
• Q&A ¦ Andrew Goodman, MD, FAAN, FANA

The Evolving Research Landscape: Understanding, Designing, and Analyzing Studies in Multiple Sclerosis

All Presentations

• Introduction to Clinical Research: When, Why, and How ¦  Kavita Nair, PhD
• Understanding and Interpreting Clinical Trial Design in Multiple Sclerosis ¦  Enrique Alvarez, MD, PhD
• Real World Observational Studies in Multiple Sclerosis ¦  Carrie Hersh, DO, MSc
• Q&A ¦  Panel

Current Topics and Trends in MS Rehabilitation (Part 2)

• MS Rehab Research: Turning a Burning Clinical Question into a Research Project  ¦  Donna Fry, PT, PhD; Herb Karpatkin, PT, DSc, NCS, MSCS; Lori Ann Kostich, MS, CCC-SLP, MSCS

Interventions for Success at Work: Research to Application

• Research Pertaining to Employment and MS ¦ Ralph H B Benedict, PhD, ABPP-CN
• Medical Management Supporting the Employed Individual ¦ Amy Neal, MS PA-C
• Supports Provided by Rehabilitation ¦ Lori Ann Kostich, MS, CCC-SLP, MSCS
• Accommodations to Help Manage the Work Environment ¦ Shaheen Virani, MA, CRC

Challenges and Considerations with Infusible Therapies

All Presentations

• Introduction ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
• Pre-infusion Preparation ¦ Colleen Harris, MN, NP, MSCN, MSCS
• Infusions and Maintenance of Therapies ¦ Denise Bruen, MSN, APRN-BC, MSCN
• Case Studies ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN

Update on Communication Skills: Using New Tools in Conversations with Patients

• Course Overview ¦ Marie Namey, APRN, MSCN
• Communication: The CPR of Healthcare ¦ E. Mary Johnson, RN, BSN, NE-BC
• Shared Decision Making: Patient Centered Health Care ¦ Marie Namey, APRN, MSCN; Ellen Reardon, RN, MSN
• Panel Discussion ¦ Panel

Fibromyalgia and Myofascial Pain in MS Patients

David Brandes, MS, MD, FAAN, MSC

An MS Health Professional’s Guide to Cannabis 

Allen C. Bowling, MD, PhD

• History, Botany, Pharmacology
• Efficacy and Safety
• Drug Interactions and Special Considerations
• The Critical Role of MS Health Professionals

Multidisciplinary Management of Chronic Pain in MS

• Introduction to Multidisciplinary Management of Chronic Pain in MS ¦ Kevin Alschuler, PhD
• Management of the MS Patient with Chronic Pain ¦ Brett R. Stacey, MD
• Is There a Role for Opioids in MS Pain Management? A Case-Based Discussion ¦ Pamela Stitzlein Davies, MS, ARNP, FAANP
• Physical Activity and Chronic Pain in MS ¦ Robert W. Motl, PhD
• Cognitive Behavioral Interventions for Chronic Pain ¦ Dawn M. Ehde, PhD
• Q&A ¦ Panel

Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)

• RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
• Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
• Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
• Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN

Fundamentals of Multiple Sclerosis Care 2019 (Part 3)

• Multidisciplinary Approach to Symptom Management ¦ Beverly Layton, RN, BSN, CCRC, MSCN
• Pearls from Advanced Practice: Disease Modifying Therapies ¦ Marie Moore, MSN, FNP, MSCN
• Emerging Role of Pharmacists in MS Centers ¦ Brittany Denson, PharmD
• Current Options in Comprehensive Fatigue Management ¦ Patricia Pagnotta, ANP-C, MSCN
• Symptoms Below the Belt: Strategies in the Management of Elimination and Sexual Dysfunction ¦ Marie Namey, APRN, MSN, MSCN

Complex Symptoms in MS: Assessment and Management Strategies

• Welcome and Overview ¦ Kathleen Costello, MS, ANP-BC, MSCN
• Balance Issues in MS ¦ Jeffrey Hebert, PhD, PT
• Spasticity and MS ¦ Susan Bennett, PT, DPT, EdD, NCS, MSCS
• Visual Disturbances ¦ Robert K. Shin, MD
• Q&A ¦ Panel

Mental Health Care Delivery Models for Patients with MS

• The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
• Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
• The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
• Q&A
• Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
• The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
• Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
• Q&A ¦ Panel

Platform Presentations: Disease Assessment and Management

• DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
• DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
• DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
• DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
• DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
• DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD

Beyond the PI: Drug-Drug Interactions (DDIs), Monitoring and Management

• Precision Medicine and Applied Pharmacology for Anti-Depressants, Anti-Psychotics to Assist in Drug Selection and Monitoring to Avert Comorbidities in Patients with MS ¦ Rebecca Barnhart, PharmD, BCPP
• Anatomy of Pharmacokinetic/ Pharmacodynamic Drug Interaction Implications ¦ Felecia Hart, PharmD, MSCS

Whitaker Platform Presentations

• Welcome and Introduction ¦ Michael Racke, MD
• A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
• Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
• Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
• Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
• Q&A, Closing ¦ Michael Racke, MD

Clinical Trials and Technology: What We Know, What is Coming?

• Responsibilities of the Investigator: Current Use of Electronic Data Capture ¦ Andrew Goodman, MD, FAAN, FANA
• Research Technology in the Clinic: A Learning Health Care System ¦ Kelsey Yoo, PA
• Telemedicine Techniques in Clinical Research: Current and Future Use ¦ Lee Gerwitz, MD
• Q&A ¦ Andrew Goodman, MD, FAAN, FANA

The Future of MS Imaging

• Welcome and Goals: Presenting the NAIMS Cooperative ¦ Daniel S. Reich, MD, PhD
• Role of Advancing Imaging in Diagnosing (and Not Misdiagnosing) MS ¦ Andrew Solomon, MD
• Stretch ¦ Daniel Reich, MD, PhD
• Role of Advanced Imaging in Predicting and Tracking MS Course ¦ Jiwon Oh, MD, PhD, FRCPC
• Role of Advanced Imaging in Unraveling MS Pathophysiology ¦ Pascal Sati, PhD
• Discussion and Wrap-up

Current Topics and Trends in MS Rehabilitation (Part 3)

• Occupational Therapy Assessment and Intervention in Multiple Sclerosis: A Behavior-based Approach ¦ Shaina Meyer, OTR/L, MSCS; Rebecca Cunningham, OTD, OTR/L
• Computer Based Rehab Outcome Measures: The Future is Now ¦ Matt Sutliff, PT, DPT, MSC

New Technology in MS

• The Brave New World of Technology ¦ Gabriel Pardo, MD, FAAN
• Digital Innovations; Reshaping How We See MS ¦ Daniel Pelletier, MD
• New Approaches to Solving Old Problems ¦ Darin Okuda, MD
• Q&A ¦ Panel

New Developments in MS Rehabilitation and Telerehabilitation (VA MSCoE)

All Presentations

• Introduction ¦ Jodie Haselkorn, MD, MPH
• Overview of Existing Telerehabilitation in MS in Current Practice ¦ Mitchell T. Wallin, MD, MPH
• Novel Applications of Telerehabilitation Technology ¦ Shane Chanpimol, PT, DPT
• Strategies to Enhance Function in MS through Rehabilitation Intensity, Duration and Timing ¦ Jodie Haselkorn, MD, MPH
• Current Evidence-based Rehabilitation Interventions for Fall Prevention in MS ¦ Michele Cameron, MD, PT, MCR
• Discussion ¦ Panel

Improving the Health and Wellness of People with Advanced MS through Community Partnerships

• Creating Partnerships for Healthier Outcomes ¦ Rachael Stacom, MS, ANP-BC, MSCN
• Building an Effective Peer Support/Mentoring Program for People Living with Multiple Sclerosis ¦ Elaine Castelluccio, PT, MPT, MSCS
• Being a Peer Mentor: The Lived Experience ¦ Cathy Kiler-McFadden

The Importance of Community Based Programs to Enhance Comprehensive MS Care

• Welcome and Introduction of Speakers ¦ Brian Hutchinson, PT, MSCS
• Community-Based Wellness Models for Chronic Disease ¦ Brian Hutchinson, PT, MSCS
• Building MS Communities, Expanding the Continuum of Care ¦ James Bowen, MD
• A Community Based Yoga Program for People with MS: The Power of Connection ¦ Megan Weigel, DNP, ARNP-c, MSCN
• The Multiple Sclerosis Achievement Center: A Day Program Model for People with MS ¦ Brian Hutchinson, PT, MSCS

Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)

• RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
• Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
• Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
• Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN

Integrative Medicine: An Essential But Neglected Component of Comprehensive MS Care

• Introduction, Relevance to Comprehensive Care, Science and Clinical Application, Research Update ¦ Allen C. Bowling, MD, PhD
• Calorie-Restriction and Other Dietary Modification Strategies for MS Course ¦ Kathryn Fitzgerald, ScD, ScM
• Constraint-Induced Movement Therapy ¦ Victor Mark, MD
• Can High Intensity Training in MS Further Optimize Exercise Therapy Outcome? ¦ Charly Keytsman, PhD

Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS

• Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS ¦ Gloria von Geldern, MD
• Encouraging Wellness Behaviors and Integrating Wellness into Neurologic Care ¦ Annette Wundes, MD
• Guiding Patients through the Complex World of MS Care ¦ Debra Cramer, RN
• Physiatry and Rehabilitation Therapy Interventions to Promote Wellness ¦ Gloria Hou, MD
• Promoting Wellness through Education, Employment, and Volunteering ¦ Joe Stuckey, MS, CRC
• Promoting Wellness Behaviors through Health Behavior Change Interventions ¦ Samantha Artherholt, PhD